Search Results - "Asbury, Peggy"

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer by RINEHART, John, ADJEI, Alex A, GULYAS, Stephen, MITCHELL, David Y, HERRERA, Roman, SEBOLT-LEOPOLD, Judith S, MEYER, Mark B, LORUSSO, Patricia M, WATERHOUSE, David, HECHT, J. Randolph, NATALE, Ronald B, HAMID, Oday, VARTERASIAN, Mary, ASBURY, Peggy, KALDJIAN, Eric P

“…This multicenter, open-label, phase II study was undertaken to assess the antitumor activity and safety of the oral mitogen-activated extracellular signal…”
Get full text

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies by Lorusso, Patricia M, Adjei, Alex A, Varterasian, Mary, Gadgeel, Shirish, Reid, Joel, Mitchell, David Y, Hanson, Lorelei, DeLuca, Pamela, Bruzek, Laura, Piens, Jill, Asbury, Peggy, Van Becelaere, Keri, Herrera, Roman, Sebolt-Leopold, Judith, Meyer, Mark B

“…This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a…”
Get full text

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology by Varterasian, Mary, Meyer, Mark, Fingert, Howard, Radlowski, Diane, Asbury, Peggy, Zhou, Xiaofeng, Healey, Diane

Get full text

Phase i and pharmacodynamic study of the oral MEK inhibitor Cl-1040 in patients with advanced malignancies : Signal transduction by LORUSSO, Patricia M, ADJEI, Alex A, ASBURY, Peggy, VAN BECELAERE, Keri, HERRERA, Roman, SEBOLT-LEOPOLD, Judith, MEYER, Mark B, VARTERASIAN, Mary, GADGEEL, Shirish, REID, Joel, MITCHELL, David Y, HANSON, Lorelei, DELUCA, Pamela, BRNZEK, Laura, PIENS, Jill

Get full text